RT Journal Article
T1 Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal
A1 Ríos Tamayo, Rafael
A1 Paiva, Bruno
A1 Lahuerta, Juan José
A1 Martínez López, Joaquín
A1 Duarte, Rafael F.
AB Monoclonal gammopathies of clinical significance (MGCSs) represent a group of diseases featuring the association of a nonmalignant B cells or plasma cells clone, the production of an M-protein, and singularly, the existence of organ damage. They present a current framework that is difficult to approach from a practical clinical perspective. Several points should be addressed in order to move further toward a better understanding. Overall, these entities are only partially included in the international classifications of diseases. Its definition and classification remain ambiguous. Remarkably, its real incidence is unknown, provided that a diagnostic biopsy is mandatory in most cases. In fact, amyloidosis AL is the final diagnosis in a large percentage of patients with renal significance. On the other hand, many of these young entities are syndromes that are based on a dynamic set of diagnostic criteria, challenging a timely diagnosis. Moreover, a specific risk score for progression is lacking. Despite the key role of the clinical laboratory in the diagnosis and prognosis of these patients, information about laboratory biomarkers is limited. Besides, the evidence accumulated for many of these entities is scarce. Hence, national and international registries are stimulated. In particular, IgM MGCS deserves special attention. Until now, therapy is far from being standardized, and it should be planned on a risk and patient-adapted basis. Finally, a comprehensive and coordinated multidisciplinary approach is needed, and specific clinical trials are encouraged.
PB MDPI
SN 2072-6694
YR 2022
FD 2022-10-26
LK https://hdl.handle.net/20.500.14352/72279
UL https://hdl.handle.net/20.500.14352/72279
LA eng
DS Docta Complutense
RD 17 abr 2025